Compare BATRK & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BATRK | IRON |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | BATRK | IRON |
|---|---|---|
| Price | $40.32 | $71.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $58.00 | ★ $108.85 |
| AVG Volume (30 Days) | 329.5K | ★ 684.5K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $723,307,000.00 | N/A |
| Revenue This Year | $12.40 | N/A |
| Revenue Next Year | $6.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.62 | N/A |
| 52 Week Low | $35.46 | $30.82 |
| 52 Week High | $47.18 | $99.50 |
| Indicator | BATRK | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 29.87 |
| Support Level | $39.71 | $76.19 |
| Resistance Level | $40.62 | $81.90 |
| Average True Range (ATR) | 0.69 | 3.36 |
| MACD | 0.05 | -0.51 |
| Stochastic Oscillator | 74.29 | 8.20 |
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.